Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree
The centerpiece of the acquisition is Myricx Bio’s novel N-myristoyltransferase inhibitor payload platform, which could help Novartis develop antibody-drug conjugates that can overcome the limitations of existing therapies.
Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree Read More »
